On April 18th BC PharmaCare announced that it was expanding its existing coverage of medications for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in the paediatric population only. Three long acting ADHD medications (Adderall XR, Vyvanse and Strattera) will be added under the Special Authority (SA) program. CADDRA and CADDAC along with BC medical practitioners welcome these expanded medication options for children. However, British Columbia continues to lag significantly behind other provinces by denying coverage to individuals over 19, thereby discriminating against adults with ADHD.
Read More on our Blog
May 2, 2017 Media Releases
For most of my life, ADHD was framed as a disorder... Read More
Attention Deficit Hyperactivity Disorder (ADHD) is... Read More
You may be wondering how I went from being an ADHD... Read More
In 2024, I had entered what I believe to be the “e... Read More
Last week, my son attended his regular swimming le... Read More
